JP2016537326A5 - - Google Patents

Download PDF

Info

Publication number
JP2016537326A5
JP2016537326A5 JP2016524077A JP2016524077A JP2016537326A5 JP 2016537326 A5 JP2016537326 A5 JP 2016537326A5 JP 2016524077 A JP2016524077 A JP 2016524077A JP 2016524077 A JP2016524077 A JP 2016524077A JP 2016537326 A5 JP2016537326 A5 JP 2016537326A5
Authority
JP
Japan
Prior art keywords
weight
fumarate
crystalline form
single crystalline
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016524077A
Other languages
English (en)
Japanese (ja)
Other versions
JP6492072B2 (ja
JP2016537326A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2014/051001 external-priority patent/WO2015054793A1/en
Publication of JP2016537326A publication Critical patent/JP2016537326A/ja
Publication of JP2016537326A5 publication Critical patent/JP2016537326A5/ja
Application granted granted Critical
Publication of JP6492072B2 publication Critical patent/JP6492072B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016524077A 2013-10-18 2014-10-17 Plk4阻害剤の塩および結晶形態 Active JP6492072B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361892564P 2013-10-18 2013-10-18
US61/892,564 2013-10-18
PCT/CA2014/051001 WO2015054793A1 (en) 2013-10-18 2014-10-17 Salt and crystal forms of plk-4 inhibitor

Publications (3)

Publication Number Publication Date
JP2016537326A JP2016537326A (ja) 2016-12-01
JP2016537326A5 true JP2016537326A5 (enExample) 2017-12-21
JP6492072B2 JP6492072B2 (ja) 2019-03-27

Family

ID=52827507

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016524077A Active JP6492072B2 (ja) 2013-10-18 2014-10-17 Plk4阻害剤の塩および結晶形態

Country Status (27)

Country Link
US (5) US9884855B2 (enExample)
EP (1) EP3057965B1 (enExample)
JP (1) JP6492072B2 (enExample)
KR (3) KR20160070106A (enExample)
CN (2) CN105764899B (enExample)
AU (1) AU2014336929B9 (enExample)
CA (1) CA2926845C (enExample)
CY (1) CY1121484T1 (enExample)
DK (1) DK3057965T3 (enExample)
EA (1) EA031569B1 (enExample)
ES (1) ES2718603T3 (enExample)
HR (1) HRP20190564T1 (enExample)
HU (1) HUE043194T2 (enExample)
IL (1) IL245038B (enExample)
LT (1) LT3057965T (enExample)
ME (1) ME03377B (enExample)
MX (1) MX359069B (enExample)
NZ (1) NZ718744A (enExample)
PL (1) PL3057965T3 (enExample)
PT (1) PT3057965T (enExample)
RS (1) RS58413B1 (enExample)
SG (1) SG11201602783SA (enExample)
SI (1) SI3057965T1 (enExample)
SM (1) SMT201900124T1 (enExample)
TR (1) TR201902875T4 (enExample)
TW (1) TWI659952B (enExample)
WO (1) WO2015054793A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2417127B1 (en) 2009-04-06 2014-02-26 University Health Network Kinase inhibitors and method of treating cancer with same
PT2556071T (pt) 2010-04-06 2016-11-22 Univ Health Network Inibidores de quinase e seus usos no tratamento de cancro
HRP20190564T1 (hr) 2013-10-18 2019-05-17 University Health Network Sol i kristalni oblici inhibitora plk-4
CN111225670A (zh) * 2017-09-08 2020-06-02 大学健康网络 抑制Polo样激酶4的组合疗法
EP3959209A4 (en) * 2019-04-24 2022-12-28 University Health Network S4 CRYSTALLINE FORM OF A PLK4 INHIBITOR (1R,2S)-(E)-2-(3-(4-((CIS-2,6-DIMETHYLMORPHOLINO)METHYL)STYRYL)-1H-IMIDAZOL-6-YL )-5'-METHOXYSPIRO[CYCLOPROPANE-L,3'-INDOLIN]-2'-ONE FUMARATE
TWI880995B (zh) * 2019-12-06 2025-04-21 加拿大健康網路大學 急性骨髓性白血病或骨髓發育不良症候群的治療
MX2023013225A (es) 2021-05-11 2024-01-15 Oric Pharmaceuticals Inc Inhibidores de la cinasa 4 similar a polo.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2483323A (en) * 1945-08-01 1949-09-27 Kay Fries Chemicals Inc Method of preparing phenyl ethyl alcohol
US7205328B2 (en) 2002-10-21 2007-04-17 Irm Llc Oxindoles with anti-HIV activity
DE102005005395A1 (de) * 2005-02-03 2006-08-10 Schering Aktiengesellschaft Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
GB0606234D0 (en) * 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
WO2008118097A1 (en) * 2007-03-23 2008-10-02 Agency For Science, Technology And Research Palladium catalysts
US20110201818A1 (en) * 2007-09-25 2011-08-18 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
JP2011506494A (ja) * 2007-12-21 2011-03-03 ユニバーシティ・ヘルス・ネットワーク 癌の治療に有用なキナーゼ阻害剤としてのインダゾリル、ベンズイミダゾリル、ベンゾトリアゾリル置換インドルモン誘導体
EP2417127B1 (en) 2009-04-06 2014-02-26 University Health Network Kinase inhibitors and method of treating cancer with same
ES2660146T3 (es) 2009-04-29 2018-03-21 Nerviano Medical Sciences S.R.L. Sales del inhibidor de cdk
PT2556071T (pt) 2010-04-06 2016-11-22 Univ Health Network Inibidores de quinase e seus usos no tratamento de cancro
WO2012000103A1 (en) 2010-07-02 2012-01-05 University Health Network Methods of targeting pten mutant diseases and compositions therefor
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
KR20130105675A (ko) * 2010-11-25 2013-09-25 라티오팜 게엠베하 아파티닙의 신규 염 및 다형
US9580390B2 (en) * 2011-10-12 2017-02-28 University Health Network Indazole compounds as kinase inhibitors and method of treating cancer with same
ES2908200T3 (es) 2013-10-18 2022-04-28 Univ Health Network Tratamiento para el cáncer de páncreas
HRP20190564T1 (hr) 2013-10-18 2019-05-17 University Health Network Sol i kristalni oblici inhibitora plk-4

Similar Documents

Publication Publication Date Title
JP2015512942A5 (enExample)
JP2017527578A5 (enExample)
AU2014219283C1 (en) Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
JP2018115191A5 (enExample)
JP2013237682A5 (enExample)
JP2010516681A5 (enExample)
JP2018024682A5 (enExample)
JP2020511467A5 (enExample)
JP2014525470A5 (enExample)
JP2016528179A5 (enExample)
JP2017061547A5 (enExample)
JP2021536511A5 (enExample)
TWI537259B (zh) 吡啶酮衍生物
JP2015509540A5 (enExample)
JP2015503610A5 (enExample)
JP2020517611A5 (enExample)
RU2013145518A (ru) Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2, 6-диона и их фармацевтические композиции и применение
JP2016503010A5 (enExample)
JP2014527042A5 (enExample)
JP2012513416A5 (enExample)
JP2016513704A5 (enExample)
JP2012526766A5 (enExample)
JP2014530818A5 (enExample)
JP2015522037A5 (enExample)
RU2015134420A (ru) Кристаллические формы { [1-циано-5-(4-хлорофеноксид)-4-гидроксид-изохинолин-3-карбонил]-амино} -уксусной кислоты